AnaptysBio (NASDAQ:ANAB) reported quarterly losses of $(1.84) per share which missed the analyst consensus estimate of $(0.92) by 100 percent. This is a 43.75 percent decrease over losses of $(1.28) per share from the same period last year. The company reported quarterly sales of $25.556 million which missed the analyst consensus estimate of $28.973 million by 11.79 percent. This is a 7.98 percent decrease over sales of $27.771 million the same period last year.